In March 2020, ozanimod capsules, agonists for S1PR1 and S1PR5, were approved for application in the treatment of relapsing forms of multiple sclerosis by the US FDA, involving clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The gene discussed is S1PR5; the disease is multiple sclerosis.